NICE pricing reform 'not radical enough' says UK drug industry group
This article was originally published in SRA
Executive Summary
NICE in the UK needs a "more radical" reform of its methods and processes than is currently being proposed in its consultation on value-based assessment (VBA), says the Association of the British Pharmaceutical Industry1-3.